← 返回

工程化巨噬细胞在乳腺癌中的应用:连接靶向治疗与先进药物递送

英文原题:Engineered macrophages in breast Cancer: bridging targeted therapy and advanced drug delivery.

查看英文原题

Engineered macrophages in breast Cancer: bridging targeted therapy and advanced drug delivery.

PubMed 2025/07/15(内容时间) Int Immunopharmacol Q1 · IF 5.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

乳腺癌(BC)仍然是全球主要的健康挑战,尽管传统疗法取得了进展,其死亡率仍然很高。免疫治疗,特别是通过工程化巨噬细胞,正成为BC治疗的一种有前景的策略。巨噬细胞在肿瘤微环境(TME)中的肿瘤进展和免疫调节中均发挥关键作用。本综述探讨了当前用于增强巨噬细胞在BC免疫治疗中治疗潜力的工程技术。我们讨论了细胞因子工程、肿瘤靶向受体如嵌合抗原受体(CAR)-巨噬细胞,以及新型药物递送平台,包括工程化巨噬细胞作为直接药物载体和作为纳米颗粒的载体。本综述还讨论了将这些策略转化为临床应用所面临的挑战,并强调了改善BC治疗结局的未来方向。

展开英文摘要原文

Breast cancer (BC) remains a major global health challenge, with significant mortality despite advancements in conventional therapies. Immunotherapy, particularly through engineered macrophages, is emerging as a promising strategy for BC treatment. Macrophages play key roles in both tumor progression and immune modulation within the tumor microenvironment (TME). This review explores current engineering techniques to enhance the therapeutic potential of macrophages in BC immunotherapy.

We discuss cytokine engineering, tumor-targeting receptors like chimeric antigen receptor (CAR)-macrophages, and novel drug delivery platforms, including engineered macrophages as direct drug carriers and as carriers for nanoparticles. The review also addresses the challenges in translating these strategies to clinical applications and highlights future directions for improving therapeutic outcomes in BC.

论文信息

作者
Qian D、Mu Y、Jiang Z、Liu H、Zhu L、Yang Z、Wu C、He C
第一作者单位
Central Laboratory, Changshu Hospital Affiliated to Soochow University, Changshu No.1 People's Hospital, Changshu 215500, China; General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China.China
通讯作者单位
General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China. Electronic address: mxlmail@126.com.China
文献类型
综述
期刊
International immunopharmacology2025 Oct 10
原文标识
PubMed 40669251 · DOI 10.1016/j.intimp.2025.115237